Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.30 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.30 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.30 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798388 | 0.82 | KDM4E (0.40) | MYCALDH1A1 | |
| SCHEMBL15415279 | 0.81 | KEAP1 (0.34) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL11077665 | 0.79 | HTR6 (0.37) | TSHRSMN1; SMN2ALDH1A1ACHE | |
| SCHEMBL11798381 | 0.77 | HSD11B1 (0.39) | MYCALDH1A1SUMO2SUMO1SENP7 | |
| SCHEMBL691617 | 0.77 | ALDH1A1 (0.35) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL483018 | 0.77 | SMN1; SMN2 (0.34) | TSHRSMN1; SMN2CA2ALDH1A1 | |
| SCHEMBL692167 | 0.77 | TTR (0.38) | TSHRSMN1; SMN2MYC | |
| SCHEMBL5152547 | 0.76 | GABRA1 (0.39) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15303121 | 0.75 | TDP2 (0.30) | — | |
| SCHEMBL458583 | 0.75 | TTR (0.41) | TSHRSMN1; SMN2CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633733-A4 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES CORP (US) | 2007-02-28 | — | — | EP | claimed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | claimed |
| JP-2007501279-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1633733-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050026077-A1 | Forming relief images; for ((opto)electronics; photoresists; mixture of binder and photoactivable compound | SHIPLEY COMPANY, L.L.C. (US) | 2005-02-03 | — | — | US | claimed |
| WO-2004113320-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-12-02 | — | — | US | claimed |
| EP-1407324-A1 | PHOTOIMAGEABLE COMPOSITION | Shipley Company LLC (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030099899-A1 | Photoimageable composition | SHIPLEY COMPANY, L.L.C. | 2003-05-29 | — | — | US | claimed |
| WO-2002091083-A1 | PHOTOIMAGEABLE COMPOSITION | SHIPLEY COMPANY, L.L.C. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | claimed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-5151430-A | Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents | MERCK & CO., INC. (US) | 1992-09-29 | — | — | US | claimed |
| EP-0071985-B1 | WATER-SOLUBLE MONO-AZO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DYESTUFFS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-03-20 | — | — | EP | claimed |
| EP-0071985-A2 | Water-soluble mono-azo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-16 | — | — | EP | claimed |
| EP-2421613-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF | The Procter & Gamble Company (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-0071985-B1 | WATER-SOLUBLE MONO-AZO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DYESTUFFS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-03-20 | — | — | EP | disclosed |
| EP-0071985-A2 | Water-soluble mono-azo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | CNR2, CNR1, GPR18 | TSHR 1808/4885SMN1; SMN2 2941/4885MYC 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.